540
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability

ORCID Icon, , , &
Pages 1292-1305 | Received 07 Dec 2018, Accepted 09 Apr 2019, Published online: 17 May 2019
 

Abstract

Olmesartan medoxomil (OM) is a hydrophobic antihypertensive drug with low bioavailability (26%) and is known to have adverse effects such as celiac disease and enteropathy. The purpose of this study was to develop SMEDDS to increase bioavailability and decrease potential side effects of OM. Hydrophilic lipophilic balance was calculated by testing solubility of OM in different oils, surfactants, and cosurfactants to obtain the most suitable combination of SMEDDS. Pseudoternary phase diagram was used to select the better oil/water formulation of SMEDDS. After a test for 3-month stability, dissolution tests and parallel artificial membrane permeability assay (PAMPA) were conducted to investigate drug solubility and permeability. Biodistribution of fluorescent marked SMEDDS was observed by using in vivo imaging system. The pharmacodynamics of the drug were determined by measuring blood pressure from tails of rats. At the end of the experiment, intestines were examined for adverse effects of OM. Compared with tablet formulation according to the dissolution study, SMEDDS formulation showed 1.67 times improvement in solubility of OM. PAMPA studies suggested a much faster permeability rate for OM SMEDDS compared to the suspension form. Labeled SMEDDS gave 3.96 times stronger fluorescent emission than control dye administered mice in in vivo imaging system (IVIS®) studies, indicating an increased bioavailability. Treating effect of SMEDDS was 3.1 times more efficient compared to suspension in hypertensive rats. It caused neither celiac-like enteropathy nor diarrhea, during 21-day noninvasive blood pressure system (NIBP) assay. Our results suggest that SMEEDS formulation improves dissolution and oral bioavailability of OM while reducing its adverse effects.

Acknowledgements

The authors acknowledge Lecturer Murat Aydemir for providing English language assistance, Prof. Dr. Mehmet Orman and Assoc. Prof. Dr. Timur Kose for providing statistical calculation support, and ARGEFAR Pre-phase Research Unit, Laboratory of Experimental Animals, Ege University (Izmir, Turkey).

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The authors express deep gratitude to Aliye Uster Foundation for their generous funding of this research. This work was also supported by the Ege University Scientific Research Project Commission (BAP), Izmir-Turkey, Grant Number 15-ECZ-014.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.